Browse > Article
http://dx.doi.org/10.4046/trd.2009.66.2.93

Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer  

Ban, Hee-Jung (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School)
Oh, In-Jae (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Kim, Kyu-Sik (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Ju, Jin-Yung (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School)
Kwon, Yong-Soo (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School)
Kim, Yu-Il (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School)
Lim, Sung-Chul (Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School)
Kim, Young-Chul (Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital)
Publication Information
Tuberculosis and Respiratory Diseases / v.66, no.2, 2009 , pp. 93-97 More about this Journal
Abstract
Background: Belotecan (Camtobell, CKD-602, Chongkundang Pharm., Korea), a camptothecin derivative, has anticancer effects by inhibiting topoisomerase I such as topotecan. This study observed the response, survival and toxicity of belotecan monotherapy after the failure of etoposide and platinum (EP). Methods: Forty nine small cell lung cancer (SCLC) patients (M/F=41/8; age, 64.5${\pm}$7.6 (mean${\pm}$SD) years), who failed in their first line chemotherapy were enrolled in this study. Twenty one SCLC patients showed relapsed lung cancer more than 90 days after their priorEP chemotherapy (sensitive relapse group, SR) and 28 patients relapsed within 90 days (refractory relapse group, RR). Results: The response rate was 25%. Eleven patients showed partial responses and 5 patients could not be checked. The response rate of the SR and RR patients was similar. The relative dose intensity was lower in the responders (78${\pm}$15%) than non-responders (83${\pm}$13%, p=0.03). The median survival time (MST) was 10.3 months (290 days). The MST of the non-responders and responders was 186 days (95% CI; 67-305) and 401 days (95% CI; 234-568, p=0.07), respectively. The median progression free survival (MPFS) was similar in the SR (79 days) and RR (67 days) patients. Grade 3-4 neutropenia, anemia, and thrombocytopenia were observed in 59.6%, 12.8% and 23.4% of patients, respectively. Conclusion: The efficacy and survival were demonstrated in the second-line setting. However, a randomized comparative trial with topotecan will be needed.
Keywords
Belotecan; Camptothecin; Small cell lung carcinoma; Relapse;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29   DOI   ScienceOn
2 Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a cancer research campaign trial. Br J Cancer 1989;59:578-83   DOI   PUBMED   ScienceOn
3 Eckardt JR, Ardizzoni A, von Pawel J, Fields S. Pooled analysis of topotecan in the second-line treatment of patients with sensitive small cell lung cancer. Proc Am Soc Clin Oncol 1997;15:1624a   DOI
4 von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67   PUBMED
5 Jeong JH, Kim SH, Choi HJ, Shin SJ, Cho BC, Kuen IC, et al. Phase II trial of belotecan in patients with relapsed small-cell lung cancer after irinotecan-containing chemotherapy. Korean J Med 2007;73:S155
6 Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 2000;922:324-5   PUBMED
7 Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96   DOI   ScienceOn
8 Rocha Lima CM, Chiappori A. Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung Cancer 2003;40:229-36   DOI   ScienceOn
9 Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123:259S-271S   DOI   PUBMED   ScienceOn
10 Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The european organization for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J Clin Oncol 1997;15:2090-6   DOI   PUBMED